Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 21st World Congress on Gastrointestinal Cancer /
Treating HER2-mutant advanced biliary tract cancer with neratinib

3rd - 7th Jul 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.07.19
Views: 948

Dr James Harding - Memorial Sloan kettering Cancer Center, New York, USA

Dr James Harding speaks to ecancer at ESMO 21st World Congress on Gastrointestinal Cancer about the phase II findings of the SUMMIT trial, reporting the trial has found clinical benefits in using neratinib to treat HER2-mutant advanced biliary tract cancer patients.

He explains that there is a great interest in using precision medicine to find therapeutic targets in biliary tract cancers, and comments on the need for genotyping to become faster, cheaper and more efficient so that this kind of treatment can become more accessible.

Dr Harding concludes by outlining the next steps of the study. 

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation